No abstract available.
Cutaneous Fistula ; Glomerulonephritis, Membranous* ; Humans ; Sarcoma, Kaposi*

Alcoholic celiac plexus blocks have been used to relieve intractable upper abdominal cancer pain. Various techniques have been proposed including the use of the X-ray and CT scanner to improve results and to avoid complications. We used the CT scanner and the X-ray fluroscope for 36 cases of alcoholic celiac plexus blocks to determine the depth and position of the needle without previous diagnostic blocks. Good to excellent pain relief occurred in more than 72% of the patients and the advantages of the use of the CT scanner showed that 1) placement of the needle tip is easily established according to the surrounding anatomical structures. 2) the operator can introduce the needle without anxiety. 3) the time required for block are saved.
Alcoholics ; Anxiety ; Celiac Plexus* ; Humans ; Needles

No abstract available.
Acute Generalized Exanthematous Pustulosis* ; Chickens* ; Eating* ; Hemodynamics* ; Lacquer*

The surgical technique of renal transplantation has been well established, but surgical complications are not uncommon and still be important factors in postoperative mortality and morbidity. From August 1990 to May 1998, we performed 250 consecutive renal transplantations at Maryknoll hospital. The authors analyzed the kinds and incidences of surgical complications in a single center by using information from hospital records. The results were as follows: 1. The overall surgical complication rate was 9.6% (24 episodes in 250 cases). 2. These were composed of 6 vascular, 8 urologic, 4 lymphatic, and 6 wound complications. 3. Vascular complication included renal artery stenosis in 1 case and bleeding and hematoma in 5 cases. 4. Urologic complication included urine leakage in 4 cases, ureter stenosis in 2 cases and bladder stone in 2 cases. 5. Lymphatic complication was all lymphoceles. 6. One case in which renal artery stenosis had occured progressed to graft loss after 4 years later. There was no complication related mortality. 7. 1 year, 3 year and 5 year graft survival rate was 97.2%, 94.8% and 90.0%, respectively. and patient survival rate was 98.0%, 95.6% and 94.7%, respectively.
Constriction, Pathologic ; Graft Survival ; Hematoma ; Hemorrhage ; Hospital Records ; Humans ; Incidence ; Kidney Transplantation ; Lymphocele ; Mortality ; Renal Artery Obstruction ; Survival Rate ; Transplants ; Ureter ; Urinary Bladder Calculi ; Wounds and Injuries

No abstract available.
Lymphedema*

This study was designed to assess the antihypertensive efficacy and overall tolerance of doxazosin in patients with mild-to-moderate essential hypertension. Doxazosin was administered in once-daily dose from 1 to 3mg to 97 patients both in a general hospital and a local clinic in rural area. These patients are composed of three groups. One group has 49 Patients treated with doxazosin monotherapy, another group with 31 patients treated with doxazosin as well as other antihypertensive drugs combined and a third group is composed of 17 patients with renal insufficiency n addition to hypertension. The patients in the third group with renal insufficiency had 2.5mg/dl-5.0mg/dl in serum creatinine. Results are as follows : 1) The study sample is composed of 37 males (38.1%) and 60 females (61.9%) with mean age 51.4 years. Among three subasmples no statistically significant difference is observed in age, sex, mean body weight and heigh at 0.05 error level. 2) A total of 47 patients (48.5%) of the 97 patients have completed twelve-week doxazosin antihypertensive treatment. At a mean dose of 4.4+/-0.4mg at twelfth week, 37 patients (78.7%) responded to doxazosin therapy. Twenty-nine(61.7% patients achieved "excellent" blood pressure control(mean sitting DBP of < or =90mmHg), and 8 patients (17.0%) showed "good respone" (10mmHg or more DBP reduction from baseline). Whereas remaining 10 patients (21.3%) showed only "fair response" (5-9mmHg DBP reduction) or "failed"(0-4mmHg DBP reduction). In doxazosin monotherapy group thirteen(68.4%) of nineteen patients showed "excellent" or "good response" at a mean dose of 4.8mg/day. Combination therapy group with eighteen patients showed 100% therapeutic success. This group had fourteen(77.8%) "excellent" and four(22.2%) "good respinse" at a mean daily dose of doxazosin 3.9mg. Renal insufficiency group with ten patients showed six(60.0%) "excellent" and four (40.0%) "failure"cases at a mean daily dose of 4.6mg. 3) The mean baseline sitting blood pressures of doxazosin monotherapy group were 175/109 whose blood pressure at twelfth week were 150/94 at a mean daily dose of 4.8mg. The baseline blood pressure of combined therapy group 180/111 were reduced to 145/91 at twelfth week at a mean daily dose of 3.9mg. Those of renal insufficiency group were 177/112 and 156/98 respectively at a mean doxazosin daily dose of 4.6mg. 4) Of the 97 study cases, adverse effect were reported in 19.6%. The most prevalent adverse effects were dizziness(11.3%), blurred vision(9.3%), headache(5.2%), most of which were mild or moderate and disappeared with or were tolerated on continued therapy. But three cases(3.1%) had to refrain from doxazosin administration due to blurred vision, dizzines, and headache. 5) The change of lipid analysis between before and after treatment in the monotherapy group with doxazosin showed 3.8% decrease of total cholesterol and 4.6% increase of HDL cholesterol and 11% increase of triglycerides, which were not statistically significant. In the combination therapy group 0.4% decrease of total cholesterol, 24.1% decrease of HDL cholesterol and 44.3% increase of triglycerides were observed. In the renal insufficiency group 4.9% decrease of total cholesterol, 22.1% decrease of HDL cholesterol, 0.1% decrease of triglycerides were observed. But all these findings have limitation in generalization due to small number of sample and a short period of observation. 6) Laboratory chemistry test results revealed no apparent treatment-related abnormalities.
Antihypertensive Agents ; Blood Pressure* ; Body Weight ; Chemistry ; Cholesterol ; Cholesterol, HDL ; Creatinine ; Doxazosin* ; Female ; Generalization (Psychology) ; Headache ; Hospitals, General ; Humans ; Hypertension ; Male ; Renal Insufficiency ; Triglycerides

PURPOSE: To evaluate the results and complications of transscleral fixation of the foldable intraocular lens(IOL). METHODS: We performed a retrospective review of the medical records of 26 patients who had undergone transscleral fixation of acrylic three-piece foldable IOL from January 2002 to April 2004 in our hospital. There were 5 eyes with aphakia, 2 with idiopathic lens subluxation, 3 with trauma, 5 with dislocation or opacification of IOL, and 11 with complicated cataract surgery. RESULTS: The mean age of the patients was 70.6 years (range, 47~87 years). The range of preoperative best corrected visual acuity (BCVA) was from light perception to 0.6. The mean preoperative refraction and mean preoperative target refraction were 2.0 +/- 6.51D (-8.5~13D) and -0.45 +/- 0.70D (-3.75~0.39D), respectively, in spherical equivalent. The mean preoperative corneal astigmatism was -1.0 +/- 0.65D (-0.25~-2.5D). The postoperative BCVA ranged between 0.02 and 1.0, and the mean refractive error was -0.66 +/- 1.15D (-3.3~1.75D) at the last follow-up visit. The mean corneal astigmatism was -1.55D +/- 1.67 (-9~-0.25D) at the last follow-up visit (p=0.99, paired t-test). CONCLUSIONS: Transscleral fixation of the foldable IOL through small incision results in fewer complications, due to the large incision and the shorter time, and therefore, instantly improved visual acuity.
Aphakia ; Astigmatism ; Cataract ; Dislocations ; Follow-Up Studies ; Humans ; Lens Subluxation ; Lenses, Intraocular* ; Medical Records ; Refractive Errors ; Retrospective Studies ; Visual Acuity

No abstract available.
Free Tissue Flaps* ; Maxilla*

Recently, the number of obesity and diabetes mellitus have increased rapidly not only in Korea but also around the world. It is even called the new pandemic of the 21st century. In Korea, the diabetes growth rate, which exceeds the obesity growth rate, is a bigger problem. Accordingly, the simultaneous treatment of diabetes and obesity has become a global issue. In this article, we will review various obesity treatments to help diabetes remission and take a look at meaningful previous study about dietary methods for obesity. This overview includes the update of medications for obesity and the practical method for clinicians in field of obesity treatment in Korea.

Obesity and infection are interacting with each other. Infection causes obesity, and obesity contributes to the occurrence and deterioration of infection. The sources of infection that cause obesity include viruses such as adenovirus, intestinal viruses, bacteria such as intestinal microbes, parasites, and the antibiotics that cause these microbes to change. The above risk factors cause chronic inflammatory reactions in the body, and in addition, obesity is further accelerated when bad eating habits are accompanied. Among the infections that occur often in obese people and worsen their condition are various viral infections such as influenza viruses and coronavirus, bacterial infections that cause urinary tract infections or periodontal infections, respiratory infections such as bronchitis, pneumonia, floor infections and infections in surgical areas. Infection in obesity increases complications, and reduces the effectiveness of antibiotics and vaccines. The mechanism between obesity and infection is a decrease in immunity resulting from increased chronic inflammation. Based on the evidence that obesity and infection cause and effect each other and interact with each other, it can be used for prevention and treatment of obesity. Studies related to the development of obesity vaccines and the maintenance of healthy intestinal microbes are under way, which is expected to reduce obesity and prevent future prevention. As a result, reducing obesity will reduce the risk and deterioration of infection.